This page shows the latest bapineuzumab news and features for those working in and with pharma, biotech and healthcare.
BACE inhibitors are designed to block the formation of the amyloid plaques that characterise the disease, unlike earlier antibody drugs such as Lilly’s solanezumab and Pfizer’s bapineuzumab which attempted
Alzheimer’s in particular has been a barren wasteland for new drugs with dozens of candidates - many targeting beta amyloid including Pfizer’s own bapineuzumab candidate - failing to have an impact
patients. A string of failed late-stage trials in established Alzheimer's - including Eli Lilly's solanezumab and Pfizer's bapineuzumab - have prompted speculation that the key to unlocking the potential
Earlier trials of amyloid-targeting therapies such as Lilly's solanezumab and Pfizer's bapineuzumab proved disappointing, but researchers speculate that giving drugs earlier in the course of the disease could
It works in a similar fashion to Pfizer's bapineuzumab and Eli Lilly's solanezumab, which both failed phase III trials in 2012, and so was not expected to behave differently
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
Work on Pfizer, J&J and Elan's bapineuzumab, Lundbeck/Myriad Genetics' Flurizan, Pfizer and Medivation's Dimebon (latrepirdine), to name a few, has come to a halt in recent years.
And despite recent disappointments involving Alzheimer's candidate bapineuzumab, the company is still committed to tackling the “huge unmet medical need” of the condition, according to Rodriguez.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...